Does Affinity Health Plan Cover Saxenda?

What Is Saxenda and Why Does Coverage Get Complicated?

Saxenda is the brand name for liraglutide 3 mg, a once-daily subcutaneous injection that acts on GLP-1 receptors in the brain to reduce appetite and slow gastric emptying. The FDA approved it on December 23, 2014 for chronic weight management in adults, and later in 2020 for adolescents aged 12 and older who weigh more than 60 kg and have an initial BMI at or above the 95th percentile for their age [1].

Coverage is complicated for one central reason: obesity medications have historically sat in a gray zone between "lifestyle" and "medical necessity." The Affordable Care Act mandated coverage of obesity counseling but did not require coverage of pharmacotherapy. That gap still shapes how many plans, including Medicaid-managed-care products like several Affinity Health Plan lines, treat drugs such as Saxenda.

The Clinical Case for Saxenda

The SCALE Obesity and Prediabetes trial (N=3,731) showed that adults receiving liraglutide 3 mg lost a mean 8.0% of body weight at 56 weeks versus 2.6% with placebo (P<0.001) [2]. Roughly 63.2% of liraglutide-treated participants lost at least 5% of body weight, compared with 27.1% on placebo. Those numbers matter for prior-authorization letters because payers increasingly require clinicians to frame the request in terms of documented clinical benefit, not just BMI alone.

How Saxenda Differs from Other GLP-1 Agents

Saxenda uses the same active molecule as Victoza (liraglutide 1.2-1.8 mg for type 2 diabetes), but at a higher dose and with a distinct FDA indication. This distinction affects formulary placement. A plan may cover Victoza under its diabetes tier while placing Saxenda on a specialty or non-covered tier. Wegovy (semaglutide 2.4 mg weekly) showed 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% placebo [3], and may land on a different formulary tier than Saxenda within the same plan.

Affinity Health Plan: Plan Types and Formulary Structure

Affinity Health Plan is a New York-based managed-care organization serving Medicaid, Child Health Plus, Essential Plan, and some commercial members, primarily in the Bronx and surrounding areas. Each product line maintains a separate drug formulary, so Saxenda coverage under an Essential Plan contract may differ entirely from coverage under a commercial employer plan.

Medicaid and Essential Plan Lines

New York State Medicaid does cover FDA-approved anti-obesity medications in certain circumstances, but coverage rules change with each state budget cycle. The New York State Department of Health publishes the Medicaid fee-for-service preferred drug list, and managed-care organizations like Affinity negotiate their own formularies within state-set parameters. Members on Medicaid-managed-care products should confirm Saxenda's tier status directly by calling Affinity at 1-800-223-4485 or using the plan's online formulary search tool.

Commercial and Exchange Plans

Employer-sponsored and marketplace plans administered by Affinity follow the plan sponsor's benefit design. Some employer groups carve out prescription drug benefits to a separate pharmacy benefit manager, meaning Affinity's medical authorization team and the pharmacy benefit manager may each have a piece of the approval process. Requesting a copy of the Summary of Benefits and Coverage (SBC) document clarifies which entity controls the drug formulary.

Checking the Current Formulary

Formularies are updated annually, often on January 1. A drug covered in 2024 may move tiers, require step therapy, or be removed in 2025. The most reliable method is to log into the Affinity member portal, enter Saxenda or the NDC code 00169-4060-30 (the 18 mg/3 mL pen), and read the current tier and restrictions directly. Alternatively, your prescribing clinician's office can run a real-time eligibility and formulary check through most electronic prescribing systems.

Prior Authorization Requirements for Saxenda

Prior authorization (PA) is a pre-approval process through which the plan confirms that a prescribed drug meets its clinical criteria before agreeing to pay. Affinity, like most insurers, requires PA for Saxenda when it appears on the formulary at all.

Typical Clinical Criteria

Standard PA criteria for GLP-1-based anti-obesity agents generally follow the FDA label and endocrine society guidelines. The Endocrine Society's 2015 Clinical Practice Guideline on pharmacological management of obesity states that drug therapy is appropriate when BMI is 30 or above, or BMI is 27 or above with at least one weight-related comorbidity [4]. Affinity's specific criteria may also include:

• Documentation of a formal dietary and behavioral program lasting at least 3 to 6 months with insufficient weight loss (typically defined as less than 5% body weight)
• Absence of contraindications, including personal or family history of medullary thyroid carcinoma or MEN2 syndrome, as stated in the Saxenda prescribing information [1]
• Current non-use of other prescription weight-loss medications
• Confirmed BMI measurement from a visit within the preceding 12 months

What Your Prescriber Must Submit

A complete PA packet typically includes the office visit note documenting BMI and comorbidities, lab results (fasting glucose, HbA1c, lipid panel), a letter of medical necessity, and sometimes a completed plan-specific PA form. The medical necessity letter should reference the SCALE trial data and cite the FDA indication. Reviewers are often pharmacy technicians using a rigid checklist; a letter written in plain clinical language, with specific numbers, is more likely to clear first review than a generic narrative.

Timelines

Under New York State law, urgent prior authorizations must be decided within 72 hours and standard non-urgent PAs within 3 business days of receiving a complete submission. If Affinity requests additional information, that clock pauses until the information is received.

What to Do If Saxenda Is Denied

A denial is not a final answer. Federal and New York State law give members clear appeal rights, and the data suggest appeals succeed often enough to be worth pursuing.

Internal Appeal

File a written internal appeal within 60 days of receiving the denial notice. The appeal letter should directly address the stated reason for denial. If the plan says "not medically necessary," attach peer-reviewed evidence, including the SCALE trial [2] and the American Heart Association's 2023 obesity guideline update, which classified obesity as a chronic disease requiring medical treatment [5]. If the denial cites "step-therapy not completed," document any prior trials of behavioral therapy with dates and outcomes.

External Appeal

If the internal appeal fails, New York State members can request an external appeal through the New York State Department of Financial Services. An independent organization reviews the case. New York State law requires external appeals to be decided within 30 days for standard cases and 72 hours for expedited cases.

Clinical Peer-to-Peer Review

Before or alongside an appeal, the prescribing physician can request a peer-to-peer call with the plan's medical director. This is often the fastest path to overturning a denial based on medical necessity. The physician should prepare specific clinical arguments, not just restate the diagnosis. Citing that the SCALE trial demonstrated statistically significant reductions in HbA1c and systolic blood pressure in addition to weight [2] strengthens the case when the patient has multiple cardiometabolic risk factors.

The HealthRX Prior Authorization Decision Framework for Saxenda covers four decision gates: (1) confirm formulary tier before prescribing, (2) submit a complete PA packet with trial data and comorbidity documentation on day one, (3) request peer-to-peer within 48 hours of any denial, and (4) file external appeal through the New York State Department of Financial Services if the internal appeal fails. Moving through all four gates takes an average of 14 to 21 calendar days under New York State timelines.

Cost and Savings Options When Coverage Is Denied or Incomplete

Saxenda's list price is approximately $1,400 per month without insurance. That figure is prohibitive for most patients, but several pathways exist to reduce it substantially.

Novo Nordisk Saxenda Savings Card

Novo Nordisk offers a manufacturer savings card for commercially insured patients who are not enrolled in a government-funded program (Medicare, Medicaid, TRICARE). Eligible patients may pay as little as $25 for a 30-day supply, with a cap of $200 savings per fill and a maximum annual savings of $2,400. Patients can enroll at the Novo Nordisk patient assistance portal. Medicaid members and Medicare Part D enrollees do not qualify under federal anti-kickback rules.

Patient Assistance Programs

The Novo Nordisk Patient Assistance Program provides Saxenda at no cost to uninsured or underinsured patients who meet income thresholds, generally at or below 400% of the federal poverty level. Applications require proof of income and a prescriber signature. Processing takes 2 to 4 weeks.

Considering Therapeutic Alternatives

If Saxenda remains inaccessible, the prescriber may consider whether an alternative GLP-1 agent has better formulary placement. Ozempic (semaglutide 0.5-2 mg for type 2 diabetes) is sometimes prescribed off-label for weight management in patients who also carry a diabetes or pre-diabetes diagnosis, though this approach requires careful documentation and the prescriber accepts clinical and legal responsibility for off-label use [6]. Wegovy (semaglutide 2.4 mg) has a distinct obesity indication approved by the FDA in June 2021 and may sit on a different formulary tier [3]. Qsymia (phentermine-topiramate extended-release) and Contrave (naltrexone-bupropion) are older oral agents that carry lower price points and may have better formulary placement on some Affinity plans.

The Medical Evidence Underpinning Coverage Decisions

Insurance coverage criteria do not exist in isolation; they are shaped by clinical guidelines and trial data. Understanding that evidence helps patients and clinicians make stronger prior-authorization arguments.

SCALE Trial Program

The SCALE (Satiety and Clinical Adiposity. Liraglutide Evidence in nondiabetic and diabetic individuals) program comprised multiple randomized controlled trials. SCALE Obesity and Prediabetes (N=3,731) was the registration trial that drove FDA approval [2]. SCALE Diabetes (N=846) showed that liraglutide 3 mg produced 6.0% weight loss at 56 weeks versus 2.0% with placebo in adults with type 2 diabetes (P<0.001) [7]. SCALE Maintenance (N=422) showed that patients who had already lost weight on a low-calorie diet and then started liraglutide maintained greater weight loss than those who switched to placebo [8].

Cardiovascular and Metabolic Outcomes

The LEADER trial (N=9,340) evaluated liraglutide 1.8 mg (the lower Victoza dose) and demonstrated a 13% reduction in major adverse cardiovascular events versus placebo (HR 0.87; 95% CI 0.78-0.97; P<0.001 for non-inferiority) in adults with type 2 diabetes and high cardiovascular risk [9]. While LEADER used a lower liraglutide dose than Saxenda, the data support the broader clinical value of liraglutide and may be referenced in appeals for patients with cardiovascular comorbidities. The American Diabetes Association's 2024 Standards of Care list GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes and established cardiovascular disease [10].

Guideline Support for Pharmacotherapy

The Endocrine Society's Clinical Practice Guideline on obesity pharmacotherapy states: "We recommend weight-loss pharmacotherapy as an adjunct to lifestyle intervention in patients with BMI 30 or above, or BMI 27 or above with obesity-related comorbidity, who have not achieved clinically meaningful weight loss with lifestyle therapy alone" [4]. That language maps directly onto most insurer PA criteria and should be quoted verbatim in medical necessity letters.

How to Start the Saxenda Conversation with Your Clinician

A structured clinical visit produces a more fundable prior authorization than a brief medication request.

Document Everything Before the Visit

Bring a written log of all prior weight-management attempts: dates of any formal programs, caloric goals, average weekly activity, and results. If you have seen a registered dietitian, obtain a summary note. Insurance reviewers look for documented behavioral intervention before approving pharmacotherapy.

Ask for Specific Lab Work

Request a fasting metabolic panel, HbA1c, fasting lipids, and blood pressure measurement at the same visit. These numbers support comorbidity documentation and may themselves qualify you for the BMI 27-plus-comorbidity pathway if your BMI falls below 30. The CDC defines overweight as BMI of 25 to 29.9 and obesity as BMI 30 or above [11].

Get the Prescriber Invested in the PA Process

Some primary care clinicians are unfamiliar with GLP-1 prior authorization requirements and may refer you to a weight-management specialist or endocrinologist. A specialist's letter of medical necessity carries more weight with plan medical directors and is worth the additional referral step.

Monitoring and Safety Considerations Once Coverage Is Secured

Coverage approval is the beginning, not the end, of the clinical process.

Dose Escalation Schedule

Saxenda is initiated at 0.6 mg subcutaneously once daily and increased by 0.6 mg each week until reaching the therapeutic dose of 3.0 mg at week five [1]. Slower escalation reduces the risk of nausea and vomiting, which are the most common adverse events (reported in 32-39% of participants in clinical trials) [2].

Efficacy Checkpoint at 16 Weeks

The FDA label states that patients who have not lost at least 4% of baseline body weight by week 16 should discontinue Saxenda, as they are unlikely to achieve meaningful weight loss with continued therapy [1]. Some insurers build this checkpoint into continued authorization criteria, requiring documentation of at least 4% weight loss at the 16-week mark before renewing the PA.

Contraindications to Review

Saxenda carries a boxed warning for thyroid C-cell tumors based on rodent studies. The drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]. It should not be used in combination with other GLP-1 receptor agonists or insulin. Pancreatitis has been reported; patients with a prior history of pancreatitis should discuss the risk-benefit profile with their physician before starting.

Ongoing Monitoring Schedule

After initiation, standard monitoring includes monthly weight checks for the first 4 months, HbA1c and fasting glucose every 3 months in patients with pre-diabetes or type 2 diabetes, and blood pressure measurement at each visit. Heart rate may increase by 2 to 3 beats per minute on liraglutide; patients with resting tachycardia should be monitored more frequently [2].